14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AYTU vs IBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin).
Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $53.7M market capitalization and -3025.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AYTU vs IBIO Key Questions & Quantitative Answers
As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas IBIO carries 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin). Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile IBIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBIO leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with IBIO at +975.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (100.0% gross margin, -3025.6% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while IBIO shifted N/A. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBIO.
AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas IBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus IBIO (-51.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, IBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.